Cargando...
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women
AIMS: Preterm birth remains a significant risk for later disability. The selective inhibition of the prostaglandin F(2α) receptor has significant advantages for a tocolytic. The prodrug OBE022 and its metabolite OBE002 are novel prostaglandin F(2α) receptor antagonists under development for treating...
Gardado en:
| Publicado en: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6046484/ https://ncbi.nlm.nih.gov/pubmed/29708281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13622 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|